[Double-blind-study on treatment with clobetasol-17-propionate and other topical corticoids (author's transl)].
90 patients suffering from chronic skin diseases-mainly psoriasis vulgaris-were treated in a double-blind-study for two weeks with topical Clobetasol-17-propionate compared with other topical corticoids. In 81% was seen a better therapeutical effect on the Clobetasol-17-propionate treated skin area.
D000287:Administration, Topical; D000293:Adolescent; D000305:Adrenal Cortex Hormones / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D001623:Betamethasone / Q000031:analogs & derivatives* / Q000627:therapeutic use; D002648:Child; D002986:Clinical Trials as Topic; D002990:Clobetasol / Q000031:analogs & derivatives* / Q000627:therapeutic use; D003899:Desoximetasone / Q000627:therapeutic use; D004060:Diflucortolone / Q000031:analogs & derivatives / Q000627:therapeutic use; D004311:Double-Blind Method; D004485:Eczema / Q000188:drug therapy; D006801:Humans; D008875:Middle Aged; D009450:Neurodermatitis / Q000188:drug therapy; D011565:Psoriasis / Q000188:drug therapy*
D000305:Adrenal Cortex Hormones; C013486:diflucortolone valerate; D003899:Desoximetasone; C011175:betamethasone-17,21-dipropionate; D001623:Betamethasone; D002990:Clobetasol; D004060:Diflucortolone
Vergleichende Studien zwischen Clobetasol-17-propionat und anderen gebräuchlichen Kortikoid-Externa im Doppelblindversuch.